We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BXLT
26
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $795K | 0.83% |
+19,673
| New | +$778K |
|
27
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $775K | 0.81% |
+15,000
| New | +$779K |
|
|
GWPH
28
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $727K | 0.76% |
77,000
+38,200
| +98% | +$2.1M |
|
29
Pfizer
PFE
$143B
| $643K | 0.67% |
22,857
+3,811
| +20% | +$109K |
|
|
FPRX
30
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $622K | 0.65% |
15,312
+4,807
| +46% | +$165K |
|
31
PUT
Biogen
BIIB
$30.4B
| $605K | 0.63% |
15,000
+3,500
| +30% | +$925K |
|
|
EMC
32
DELISTED
EMC CORPORATION
EMC
| $600K | 0.63% |
22,500
+12,500
| +125% | +$317K |
|
|
ALXN
33
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $585K | 0.61% |
17,000
+7,000
| +70% | +$1.03M |
|
34
Apple
AAPL
$4.9T
| $584K | 0.61% |
+21,428
| New | +$534K |
|
35
AbbVie
ABBV
$450B
| $566K | 0.59% |
+9,906
| New | +$552K |
|
|
RLYP
36
DELISTED
RELYPSA INC COM
RLYP
| $562K | 0.59% |
41,484
-24,053
| -37% | -$409K |
|
|
ESPR
37
DELISTED
Esperion Therapeutics
ESPR
| $529K | 0.55% |
31,296
+21,296
| +213% | +$343K |
|
38
CALL
Coca-Cola
KO
$351B
| $525K | 0.55% |
+382,000
| New | +$16.6M |
|
39
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $516K | 0.54% |
+135,000
| New | +$26.3M |
|
|
40
PUT
Gilead Sciences
GILD
$167B
| $507K | 0.53% |
274,000
-29,000
| -10% | -$2.62M |
|
|
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
| $497K | 0.52% |
3,573
-2,114
| -37% | -$310K |
|
42
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
| $491K | 0.51% |
+45,000
| New | +$2.99M |
|
43
Larimar Therapeutics
LRMR
$384M
| $464K | 0.49% |
5,787
-861
| -13% | -$68K |
|
44
CALL
Mattel
MAT
$4.16B
| $448K | 0.47% |
50,000
| – | – |
|
45
Intel
INTC
$478B
| $425K | 0.45% |
+13,138
| New | +$403K |
|
|
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $424K | 0.44% |
+26,711
| New | +$475K |
|
47
CALL
Sarepta Therapeutics
SRPT
$1.82B
| $417K | 0.44% |
107,700
-371,700
| -78% | -$6.49M |
|
48
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
| $397K | 0.42% |
+114,700
| New | +$2.5M |
|
|
AGN
49
DELISTED
Allergan plc
AGN
| $397K | 0.42% |
1,480
-4,189
| -74% | -$1.2M |
|
|
ALDR
50
DELISTED
Alder Biopharmaceuticals
ALDR
| $396K | 0.41% |
16,173
+7,457
| +86% | +$173K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.